Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FertilityBlend study

This article was originally published in The Tan Sheet

Executive Summary

Multi-center trial on Daily Wellness Company's FertilityBlend supplements for women, men will follow 200 couples who have tried for over six months to become pregnant. Three-month trial builds on pilot study of 29 women that resulted in pregnancies for four of 14 women in treatment group, compared with no pregnancies in placebo arm. FertilityBlend for women contains chasteberry, l-arginine; men's product has l-carnitine, ferulic acid to "improve the health of sperm," firm says. Supplement is available nationwide at food, drug outlets, health food stores such as GNC...

You may also be interested in...



FertilityBlend

"Nutritional supplementation may provide an attractive alternative or complement to conventional fertility therapy," according to a study published in the April Journal of Reproductive Medicine. The double-blind placebo-controlled study followed thirty women aged 24-46 who had tried unsucessfully to conceive for 6 to 36 months. Women received three capsules of either FertilityBlend or placebo per day for three menstrual cycles. After five months, five of the 15 women in the supplement group were pregnant compared to no pregnancies in the placebo group, Lynn Westphal, MD, Department of Obstetrics & Gynecology, Stanford University, et al. find. Daily Wellness Company's FertilityBlend contains chasteberry, l-arganine. An earlier study evaluating the supplement was announced in 2002 (1"The Tan Sheet" May 20, 2002, In Brief)...

Sales Already Growing As Vascepa Secures Cardio Approval

MTI Outlook 2020: Medtechs Enter The Decade Of Digital, Consumers and Wellness

For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?

Topics

UsernamePublicRestriction

Register

PS094033

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel